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To determine the effect of dual-strain probiotics on the development of necrotizing enteroco-
litis (NEC), mortality and nosocomial bloodstream infections (BSI) in preterm infants in Ger-
man neonatal intensive care units (NICUs).
Design
Amulti-center interrupted time series analysis.
Setting
44 German NICUs with routine use of dual-strain probiotics on neonatal ward level.
Patients
Preterm infants documented by NEO-KISS, the German surveillance system for nosoco-
mial infections in preterm infants with birth weights below 1,500 g, between 2004 and 2014.
Intervention
Routine use of dual-strain probiotics containing Lactobacillus acidophilus and Bifidobacter-
ium spp. (Infloran) on the neonatal ward level.
Main outcomemeasures
Incidences of NEC, overall mortality, mortality following NEC and nosocomial BSI.
Results
Data from 10,890 preterm infants in 44 neonatal wards was included in this study. Inci-
dences of NEC and BSI were 2.5% (n = 274) and 15.0%, (n = 1631), respectively. Mortality
rate was 6.1% (n = 665). The use of dual-strain probiotics significantly reduced the risk of
NEC (HR = 0.48; 95% CI = 0.38–0.62), overall mortality (HR = 0.60, 95% CI = 0.44–0.83),
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Participation in NEO-KISS is confidential according to
the data privacy act. In addition, due to the small
number of preterm infants in Germany information
like month and year of birth, birth weight and location
might enable an interested researcher to track back
the identity of the preterm infant. To exclude this rare
possibility, data used for this study (NEO-KISS,
survey on use of probiotics) can be obtained in
anonymous and condensed form only according to
the data privacy act. Interested researchers have the
mortality after NEC (HR = 0.51, 95% CI = 0.26–0.999) and nosocomial BSI (HR = 0.89, 95%
CI = 0.81–0.98). These effects were even more pronounced in the subgroup analysis of pre-
term infants with birth weights below 1,000 g.
Conclusion
In order to reduce NEC and mortality in preterm infants, it is advisable to add routine prophy-
laxis with dual-strain probiotics to clinical practice in neonatal wards.
Introduction
Preterm infants weighing less than 1,500 g, very low birth weight (VLBW) infants, represent a
very vulnerable group of newborns. Among them, infants with births weight less than 1,000 g
constitute the subgroup of extremely low birth weight (ELBW) infants. Both, VLBW and in
particular ELBW infants, are at a high risk to develop life-threatening complications such as
necrotizing enterocolitis (NEC) and bloodstream infections (BSI) [1].
NEC is the most common complication of the gastrointestinal tract in VLBW infants [2–4].
Data from NEO-KISS, the German national surveillance system for nosocomial infections in
VLBW infants, reported 962 (2.9%) cases of NEC among 33,048 VLBW infants between 2007
and 2011 [5]. The frequency of NEC, however, varies by country and neonatal intensive care
unit (NICU) [2]. In German NICUs, NEC is associated with a high attributable mortality of
14.7% [6]. Nosocomial BSI is one of the most frequent complications of VLBW infants. 5,735
cases of nosocomial BSI (17.4%) among 33,048 VLBW infants were observed by NEO-KISS
between 2007 and 2011 [5]. The attributable mortality of BSI in German NICUs was calculated
1.4% [6]. Thus, due to the high frequency of BSI and high attributable mortality of NEC in pre-
term infants, prevention of these complications should be of high priority.
Probiotics colonize the gastrointestinal tract and have the potential to provide many benefi-
cial effects to the host [7]. Recently, several meta-analyses demonstrated that probiotics signifi-
cantly reduced the risk of NEC and overall mortality in preterm infants [8–12]. Even though
breast milk is known to reduce the risk of NEC [13, 14], probiotics turned out to be beneficial
also in studies comparing mother’s breast milk with and without supplementation of probiotics
[15–18]. Best effects were obtained for multiple-strain probiotics (e.g. Infloran) that contain
Lactobacillus acidophilus and Bifidobacterium infantis [11, 16, 17, 19–23]. However, probiotic
treatment of preterm infants is not routine practice in many neonatal departments. Reasons
for this are mainly controversial debates about the safety of probiotics, but also uncertainty in
the choice of probiotic products, strains and protocols [17]. One safety issue concerns the effect
of probiotics on the development of BSI. Three cases of bacteremia with the probiotic species
Bifidobacterium spp. were described recently in newborns receiving probiotics in a Swiss and a
German NICU [24, 25]. Further, a Taiwanese randomized control trial (RCT) including 430
preterm infants reported a higher, but not statistically significant Gram-negative BSI rate in the
study group that received probiotics [16]. However, all meta-analyses and systematic reviews
recently conducted on this topic reported unchanged [8, 10, 12, 26, 27] or even lower [28] BSI
rates after probiotic treatment. Another safety issue refers to the quality of commercially avail-
able probiotics. For use in preterm infants only probiotics produced under strict quality control
conditions should be recommended. This is the case for probiotic products with licensing as a
drug by a regulatory authority such as Infloran [23].
The aim of this study was to assess and evaluate complications of preterm birth (NEC, over-
all mortality, mortality following NEC and nosocomial BSI) in VLBW infants before and after
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the implementation of dual-strain probiotics. In addition, a subgroup analysis in ELBW infants




This retrospective multi-center study is based on NEO-KISS, the German surveillance system
for nosocomial infections in VLBW infants. Since 2005, all NICUs caring for VLBW infants in
Germany participate in this patient-based prospective surveillance system in order to receive
reimbursement [5]. Full data collection has already been conducted by German NICUs that
voluntarily participated in NEO-KISS since 2000 [5]. In NEO-KISS, surveillance is conducted
by trained nurses and doctors who collect demographic data (e.g. birth weight, sex, admission
date, gestational age, date of discharge), type of delivery and clinical data (e.g. type of infection,
clinical findings, device association) for all VLBW infants. Surveillance by the NEO-KISS data-
base ends, when the infant weighs more than 1,800 g, dies or is transferred to another
department.
Study design and setting
This multi-center time series analysis used NEO-KISS data between 2004 and 2014. In 2011, a
survey about routine administration of probiotics was conducted among all German NICUs
(n = 229). 168 (73.4%) NICUs responded. All neonatal wards that did not use prophylactic
enteral probiotics at all (n = 109), or did not provide sufficient data (n = 11) were excluded
from analysis. For validation purposes, the remaining 48 NICUs were contacted by email and/
or phone in a second survey in 2014. NICUs that did not respond (n = 1), did not routinely
administer probiotics (n = 2) or used probiotic products with a single probiotic species (n = 1)
were also excluded from analysis. NICUs were included in the study, if they met the following
inclusion criteria: i) routine use of prophylactic enteral probiotics with a multiple-strain prod-
uct such as Infloran containing Lactobacillus acidophilus and Bifidobacterium spp. on the neo-
natal ward level, ii) definition of a start date of implementation, iii) validation of their data in a
second survey (2014). 44 NICUs fulfilled the inclusion criteria and provided sufficient data
before and after the start of the exposure. A flow chart of included NICUs is depicted in S1 Fig.
Characteristics of all NICUs included are shown in S1 Table.
Probiotic product
All NICUs included in this study used Infloran (Laboratorio Farmaceutico, Mede, Italy), a
commercially available combination of Lactobacillus acidophilus and Bifidobacterium infantis.
Infloran is licensed by the Swiss Agency for Therapeutic Products of the Federal Office of Pub-
lic Health in Switzerland (#00679), SwissMedic, as a drug for use in infants with diarrhea [23].
In consequence, this dual-strain probiotic product is available in drug quality.
Patients
For the statistical analyses, all preterm infants from the 44 departments included that were
admitted between 36 months before and 36 months after the start of exposure (the start date of
routine administration of dual-strain probiotics) were considered for analysis. Infants with
admission before and discharge after the start of exposure and infants within the first 30 days
of the start of exposure (wash-in phase) were excluded. Additionally, infants with missing val-
ues in patient based confounding parameters were excluded.
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Primary and secondary outcomes
The primary outcome of this study was NEC until achieving 1800 g, transfer from NICU or
death. Secondary outcomes were overall mortality, mortality following NEC and nosocomial
primary BSI. Nosocomial BSI was defined as BSI acquired in hospital after the first 72 h of life
or 72 h after admission. Criteria for the diagnosis of NEC and BSI were recently described by
the European Center for Disease Prevention and Control (ECDC) [29]. The NEO-KISS proto-
col with definitions of NEC and BSI can be found at http://www.nrz-hygiene.de/fileadmin/nrz/
module/neo/NEO-KISSProtocol_english_240210.pdf.
NEC
For the diagnosis of NEC a combination of one radiological sign (pneumoperitoneum; pneu-
matosis intestinalis; unchanged rigid loops of small intestine) and two clinical symptoms (vom-
iting, abdominal distention, persistent microscopic or gross blood in stools, redness of regio
abdominalis lateralis (flanks) and prefeeding residuals) is required. Alternatively, a documenta-
tion of histological diagnosis based on prepared specimens was judged as a criterion for NEC.
Histological diagnosis of NEC was taken as proof of NEC and evidence for the distinction from
spontaneous perforation of intestine (SPI) [29].
According to the literature, radiographic signs are known to have a high specificity and a low
sensitivity [30, 31]. “Fixed loops of the small intestine” was defined as good indication for opera-
tion in NEC with a prevalence of 8.5%, a sensitivity of 12.5% and a specificity of 100% [32]. Cour-
sey and colleagues reported “rigid / fixed bowel loops” as an indicator of severity of illness in
neonates with NEC. They found this symptom in 10 of 43 (23.3%) infants with suspected NEC,
who underwent surgery and in 0 of 86 infants with suspected NEC without surgery [30].
Mortality following NEC was defined by death chronologically after the diagnosis of NEC
until end of surveillance.
In NEO-KISS, histological diagnosis of NEC can be documented voluntarily. A histologic
specimen was obtained during surgery and could be an indicator for severe cases of NEC [33].
NEC was stratified by NEC type (No NEC, surgical NEC, medical NEC, NEC type unknown)
to account for severity. Surgical NEC was defined as NEC with histological diagnosis (after sur-
gery), medical NEC was defined as NEC clinically diagnosed with information that no histolog-
ical specimen was obtained. NEC type unknown was defined as clinically diagnosed without
information on histology. The category no NEC included preterm infants without diagnosis of
NEC. Surgery was assumed to be an indicator of severe cases of NEC [33].
BSI
The cases of primary BSI were stratified in clinically-diagnosed BSI and laboratory-confirmed
diagnosis of BSI. The latter was further classified by proven pathogens in two groups, coagulase
negative staphylococci only (CoNS) or other than CoNS [29]. CVC- and PVC-associated BSI
were defined as a BSI with CVC or PVC present at the onset of the infection.
Clinically-diagnosed BSI. For the definition of clinically-diagnosed BSI all of the follow-
ing criteria must be met:
• Treating physician instituted appropriate antimicrobial therapy for BSI for at least 5 days. A
therapy day was similar to an antibiotic day in that it was a “day on which a patient received
systematic antibiotic (oral or parenteral)”. The day on which the first dosage was given was
counted as the first therapy day, and the day on which the last dosage was given was counted
as the last therapy day. This was independent of the number of dosages, their presumed effec-
tiveness or the duration of their effects.
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• No pathogens detected in blood culture or blood cultures were not performed. One-time evi-
dence of CoNS in blood culture could not exclude the diagnosis of clinical BSI. Clinical BSI
could also be diagnosed under the following conditions: i) CoNS appeared once in blood cul-
ture, but could be considered contamination of the blood culture and ii) remaining criteria
for CoNS BSI were not fulfilled, but the criteria for clinical BSI were fulfilled.
• No apparent infection at another site.
• In addition, two of the following criteria must be met (without other recognized cause):
fever> 38°C, hypothermia< 36.5°C or temperature instability, tachycardia (> 200 / min) or
new / more frequent bradycardia (< 80 / min), new or more frequent apnoea (> 20 sec),
extended recapillarization time (> 2 sec), unexplained metabolic acidosis (BE< -10 mEq/l),
new hyperglycaemia (> 140 mg/dl), other signs of BSI such as skin color (when recapillariza-
tion time is not used), laboratory evidence (C-reactive protein, interleukin), increased O2
requirement (intubation), unstable condition, apathy. Interleukin must be used as a parame-
ter when laboratory specifications for a pathological value were fulfilled. Interleukin 6–8 was
considered.
Laboratory-confirmed BSI. Laboratory-confirmed BSI with pathogens other than CoNS
required the following criteria:
• A recognized pathogen other than CoNS cultured from blood or cerebrospinal fluid. The lat-
ter was included because meningitis in VLBW infants is usually haematogenous. Thus, posi-
tive cerebrospinal fluid could be regarded as evidence of BSI even if blood culture were
negative or not taken. The pathogen must not be related to infections at other sites.
• In addition, at least two of these symptoms must be present: fever> 38°C, hypothermia<
36.5°C or temperature instability, tachycardia (> 200 / min) or new / more frequent brady-
cardia (< 80 / min), new or more frequent apnoea (> 20 sec), extended recapillarization
time (> 2 sec), unexplained metabolic acidosis (BE< -10 mEq/l), new hyperglycaemia
(> 140 mg/dl), other signs of BSI such as skin color (when recapillarization time is not used),
laboratory evidence (C-reactive protein, interleukin), increased O2 requirement (intubation),
unstable condition, apathy. Interleukin must be used as a parameter when laboratory specifi-
cations for a pathological value were fulfilled. Interleukin 6–8 was considered.
The definition laboratory-confirmed BSI with CoNS required the following criteria:
• Presence of CoNS in blood or isolated from catheter tip as sole pathogen
• And one of the following laboratory parameters (without another recognized cause) had to
be fulfilled: thrombocytes< 100 / nl, ratio between immature granulocytes and total
granulocytes> 0.2, leukocytes< 5 / nl (without erythroblasts), C-reactive protein> 2.0 mg /
ml or interleukin.
• In addition two of the following criteria (without another recognized cause) needed to be fulfilled:
fever> 38°C, hypothermia< 36.5°C or temperature instability, tachycardia (> 200 / min) or
new / more frequent bradycardia (< 80 / min), new or more frequent apnoea (> 20 sec),
extended recapillarization time (> 2 sec), unexplained metabolic acidosis (BE< -10 mEq/l), new
hyperglycaemia (> 140 mg/dl), other signs of BSI such as skin color (when recapillarization time
is not used), laboratory evidence (C-reactive protein, interleukin), increased O2 requirement
(intubation), unstable condition, apathy. Interleukin must be used as a parameter when labora-
tory specifications for a pathological value were fulfilled. Interleukin 6–8 was considered.
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Patient and NICU associated risk factors
The following patient associated risk factors and confounders were considered in the analyses:
birth weight in 250 g steps (< 500 g, 500–749 g, 750–999 g, 1000–1249 g, 1250–1499 g), gesta-
tional age defined as completed week of pregnancy (< 27, 27–28, 29–30,> 30 weeks), sex (male/
female), mode of delivery (planned Caesarian section, emergency Caesarian section, vaginal
delivery), birth location (inhouse, immediate postnatal transport defined by admission 72 h
after birth, longterm postnatal transport defined by admission> 72 h after birth, missing) and
pneumonia. Criteria for the diagnosis of pneumonia can be found in the NEO-KISS protocol
(http://www.nrz-hygiene.de/fileadmin/nrz/module/neo/NEO-KISSProtocol_english_240210.
pdf) and were recently described by the ECDC [29]. Briefly, one radiological finding (new or pro-
gressive infiltrate, shadowing, fluid in the interpleural cavity or interlobar fissure) in combination
with deterioration in oxygenation and at least four other clinical findings (temperature> 38°C
or< 36.5°C or temperature instability, tachycardia or bradycardia, tachypnoea or apnoea, dys-
pnoea, increased respiratory secretions, new onset of purulent sputum, isolation of a pathogen
from respiratory secretions, C-reactive protein> 2.0 mg/dL, I/T ratio> 0.2) were required to
diagnose pneumonia. Patients with severe infections suffer from BSI and / or pneumonia.
The covariable small for gestational age (SGA) was defined as birth weight< 10% percentile,
appropriate for gestational age (AGA) as 10–90% percentile, and large for gestational age (LGA)
as> 90% percentile based on population-based percentiles, separately for male and female
infants as well as for singletons and twins. Twin percentiles were used for all multiple births.
In addition, the following NICU associated risk factors and confounders were used for the
analyses: level of center (level I or II perinatal center, obstetrical hospital), type of hospital (uni-
versity hospital, other teaching hospital, others), size of department (< 20 or 20 beds),
annual number of admission in 2010 (< 30, 30–59, 60 VLBW infants) and year (as indicator
of improvement in neonatal care). Only infants with complete information about all relevant
risk factors were included in the analyses.
Statistical methods
Time series analysis was conducted for patients admitted between 36 months before and 36
months after routine administration of dual-strain probiotics. Half-yearly incidences of primary
outcomes were chosen to visualize potential fluctuations of the incidences. In the descriptive
analyses percent or median and interquartile range (25% and 75% percentile) were calculated.
Differences were tested by Chi-square test. P-values less than 0.05 were considered significant.
Interrupted time series analysis was used to evaluate longitudinal effects of routine probiotic
medication on the frequency of NEC, overall mortality, mortality following NEC and nosoco-
mial BSI [34].
Cox-proportional hazard regression was performed in the multivariable analysis to calculate
adjusted hazard-ratios (HR) with 95% confidence intervals (95% CI) and evaluate the effect of
probiotics. All confounding parameters were parameterized as continuous or dummy parame-
ters and added one degree of freedom to the model. The multivariable model building strategy
was performed in a stepwise approach. The selection criterion for including parameter in the
model was p 0.05 and for excluding p 0.06. P-values less than 0.05 were considered signifi-
cant. All analyses were performed using SPSS (IBM SPSS statistics, Somer, NY, USA) and SAS
(SAS Institute, Cary, NC, USA).
Ethics / data security
The purpose of this study was to improve quality of neonatal care by analyzing anonymous
unit-based data collected by hospitals in accordance with the German “Protection against
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Infection Act” [35]. Therefore ethical approval and informed consent were not required and
institutional review boards were not consulted.
Results
The intervention was introduced in July 2010 (January 2010–September 2010) [Median (IQR)]. In
the 44 departments, 11,448 infants were admitted 36 months before or after the start date of inter-
vention. 358 infants that were admitted before and discharged after the start of intervention or
admitted between the start of intervention and 30 days after the start (“wash in”-phase) were
excluded from analysis. An additional 200 infants were excluded due to missing values in patient
based confounding parameters. 10,890 infants were included in the analysis. A flow chart summa-
rizing the VLBW infants eligible for this study is depicted in Fig 1. The descriptive analysis of all
10,890 VLBW infants included, stratified by routine use of probiotics, is documented in Table 1.
S2 Table depicts the descriptive analysis of all 4,683 ELBW infants included, stratified by
routine use of probiotics.
NEC
Of the 10,890 VLBW infants eligible for this study, 2.5% (n = 274) suffered from NEC. 4.6% of
4,683 ELBW infants (n = 215) developed NEC during the study period. The half-yearly
Fig 1. Flow chart of VLBW infants eligible for this study.
doi:10.1371/journal.pone.0158136.g001
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Table 1. Descriptive characteristics of 10,890 VLBW infants included in the study (stratified by routine use of probiotics).
No probiotics Probiotics
Parameter Number (%) or median (IQR) Number (%) or median (IQR) P-value
Patients 5072 (100.0%) 5818 (100.0%)
Birth weight [250g steps]
< 500 g 151 (3.0%) 249 (4.3%) <0.001*
500–749 g 808 (15.9%) 961 (16.5%)
750–999 g 1178 (23.2%) 1336 (23.0%)
1000–1249 g 1132 (22.3%) 1402 (24.1%)
1250–1499 g 1803 (35.5%) 1870 (32.1%)
Gestational age [days] 203 (188–217) 202 (187–216)
Gestational age [group]
< 27 weeks 1282 (25.3%) 1599 (27.5%) 0.013*
27–28 weeks 1167 (23.0%) 1387 (23.8%)
29–30 weeks 1304 (25.7%) 1411 (24.3%)
> 30 weeks 1319 (26.0%) 1421 (24.4%)
Female sex 2451 (48.3%) 2888 (49.6%) 0.171
Delivery mode
Caesarean section 4216 (83.1%) 4889 (84.0%) 0.008*
Emergency Caesarean section 337 (6.6%) 428 (7.4%)
Vaginal 517 (10.2%) 501 (8.6%)
Missing 2 (0.0%) 0 (0.0%)
Multiple birth 1577 (31.1%) 1895 (32.6%) 0.099
CRIB Score 2 (1–6) 2 (1–5)
Surveillance end point
Over 1800 g 4276 (84.3%) 4961 (85.3%) 0.065
Transfer 463 (9.1%) 521 (9.0%)
Death 329 (6.5%) 336 (5.8%)
Missing 4 (0.1%) 0 (0.0%)
Died 329 (6.5%) 336 (5.8%) 0.122
Birth location
Inhouse birth 4662 (91.9%) 5506 (94.6%) <0.001*
Immediate postnatal transport 177 (3.5%) 159 (2.7%)
Longterm postnatal transport 93 (1.8%) 150 (2.6%)
Missing 140 (2.8%) 3 (0.1%)
NICU days 33 (23–50) 33 (22–49)
NICU days [group]
< 21 947 (18.7%) 1223 (21.0%) 0.007*
21–34 1700 (33.5%) 1858 (31.9%)
35–48 1049 (20.7%) 1240 (21.3%)
> 48 1376 (27.1%) 1497 (25.7%)
CVC days 6 (0–13) 6 (0–13)
PVC days 8 (3–14) 7 (2–12)
ETT days 0 (0–5) 0 (0–4)
CPAP days 5 (1–20) 8 (2–26)
Antibiotic days 7 (3–14) 6 (2–12)
CVC use 2998 (59.1%) 3443 (59.2%) 0.941
PVC use 4446 (87.7%) 5019 (86.3%) 0.032*
VC use 4996 (98.5%) 5659 (97.3%) <0.001*
(Continued)
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Table 1. (Continued)
No probiotics Probiotics
Parameter Number (%) or median (IQR) Number (%) or median (IQR) P-value
ETT use 2379 (46.9%) 2622 (45.1%) 0.055
CPAP use 4004 (78.9%) 4823 (82.9%) <0.001*
Respiratory support 4353 (85.8%) 5151 (88.5%) <0.001*
Antibiotic use 4090 (80.6%) 4485 (77.1%) <0.001*
Severe infection (BSI and/or
pneumonia)
904 (17.8%) 951 (16.3%) 0.041*
Pneumonia 155 (3.1%) 142 (2.4%) 0.049*
BSI 785 (15.5%) 846 (14.5%) 0.172
CVC-associated BSI 357 (7.0%) 363 (6.2%) 0.094
PVC-associated BSI 348 (6.9%) 349 (6.0%) 0.067
CVC- and PVC-associated BSI 680 (13.4%) 694 (11.9%) 0.020*
NEC 174 (3.4%) 100 (1.7%) <0.001*
NEC type
No NEC 4898 (96.6%) 5718 (98.3%) <0.001*
Surgical NEC 73 (1.4%) 54 (0.9%)
Medical NEC 56 (1.1%) 22 (0.4%)
NEC type unknown 45 (0.9%) 24 (0.4%)
Time to ﬁrst NEC [days] 18 (10–29) 15 (10–24)
Time from ﬁrst NEC to end of
surveillance [days]
22 (4–49) 36 (9–61)
Time to ﬁrst NEC or discharge 33 (23–49) 32 (22–48)
Birth year
2004 25 (0.5%) 0 (0.0%) <0.001*
2005 27 (0.5%) 0 (0.0%)
2006 242 (4.8%) 18 (0.3%)
2007 917 (18.1%) 30 (0.5%)
2008 1646 (32.5%) 73 (1.3%)
2009 1474 (29.1%) 398 (6.8%)
2010 687 (13.5%) 1161 (20.0%)
2011 52 (1.0%) 1720 (29.6%)
2012 2 (0.0%) 1550 (26.6%)
2013 0 (0.0%) 811 (13.9%)
2014 0 (0.0%) 57 (1.0%)
Size of unit [beds]
< 20 1298 (25.6%) 1674 (28.8%) <0.001*
 20 3774 (74.4%) 4144 (71.2%)
Size of hospital [beds]
< 600 1972 (38.9%) 2267 (39.0%) 0.928
 600 3100 (61.1%) 3551 (61.0%)
Neonatal care level
Perinatal center level I 5011 (98.8%) 5719 (98.3%) 0.067
Perinatal center level II 45 (0.9%) 79 (1.4%)
Obstetric clinic 16 (0.3%) 20 (0.3%)
Type of hospital
University hospital 1870 (36.9%) 2125 (36.5%) 0.542
Other teaching hospital 2853 (56.3%) 3261 (56.1%)
(Continued)
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incidences of NEC (per 100 VLBW or ELBW infants) decreased with routine use of dual-strain
probiotics (Fig 2A and 2B). The Cox proportional hazard regression identified routine probi-
otic treatment to be protective against NEC in VLBW and ELBW infants (Table 2). Further
independent risk and protective factors for NEC in VLBW and ELBW infants are summarized
in Table 2.
Mortality
665 of 10,890 VLBW infants (6.1%) died during the study period. Mortality rate was 11.9%
among ELBW infants (557 of 4,683). The half-yearly overall mortality rates (per 100 VLBW or
ELBW infants) are shown in Fig 3. Probiotics were associated with lower mortality in VLBW
and ELBW infants (Table 3). Further independent risk factors identified by Cox proportional
hazard regression for VLBW and ELBW infants are summarized in Table 3.
Mortality following NEC
44 of the 274 VLBW infants (16.1%) suffering from NEC died. Median time from diagnosis of
NEC to death was 6 days (IQR 2–15 days). In the ELBW cohort 39 of the 215 infants suffering
from NEC (18.1%) died. The half-yearly mortality rates (per 100 VLBW or ELBW infants with
NEC) decreased after routine use of probiotics (S2A and S2B Fig). The multivariable analyses
identified that probiotics improved survival of VLBW and ELBW infants suffering from NEC
(Table 4). Independent risk factors for mortality following NEC in VLBW and ELBW infants
are shown in Table 4. The cumulative survival function for mortality following NEC demon-
strated that especially within the first days of NEC probiotics seemed to be beneficial for sur-
vival of preterm infants (S3A and S3B Fig).
BSI
1,631 of 10,890 VLBW infants (15.0%) suffered from nosocomial BSI during the study period.
24.2% of 4,683 ELBW infants (n = 1,133) developed nosocomial BSI. 851 of 1,631 BSI were
clinically-diagnosed, 385 were laboratory-confirmed with proof of pathogen other than CoNS
and 395 BSI were laboratory-confirmed with CoNS as sole pathogen. A decrease of half-yearly
incidences of nosocomial BSI among 10,890 VLBW and 4,683 ELBW infants is shown in Fig
4A and 4B. The multivariable analysis suggested that probiotics were associated with lower
Table 1. (Continued)
No probiotics Probiotics
Parameter Number (%) or median (IQR) Number (%) or median (IQR) P-value
Other hospital 349 (6.9%) 432 (7.4%)
Growth
AGA 3434 (67.7%) 3992 (68.6%) 0.015*
SGA 1463 (28.8%) 1638 (28.2%)
LGA 164 (3.2%) 157 (2.7%)
Missing 11 (0.2%) 31 (0.5%)
AGA–Appropriate for gestational age, BSI- blood stream infection, CPAP–Continuous nasal positive airway pressure, CRIB–Clinical risk index for babies,
CVC–Central venous catheter, ETT–Endotracheal tube, IQR–interquartile range, LGA–Large for gestational age, Patient days–Total days present on
department, PVC–Peripheral venous catheter, Respiratory support includes CPAP and ETT, SGA–Small for gestational age, VC–Venous catheter. Chi-
square statistics were performed for categorical variables.
* P-values < 0.05 were interpreted as signiﬁcant.
doi:10.1371/journal.pone.0158136.t001
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Fig 2. NEC in VLBW infants (A) and in ELBW infants (B) treated in 44 neonatal departments before and after the routine
medication of probiotics. Half-yearly incidences of NEC in 10,890 VLBW infants (A) and in 4,683 ELBW infants (B) treated in 44
neonatal departments before and after the routine medication of probiotics. The grey line represents the trend of NEC incidences (per 100
VLBW/ELBW infants) before and after the introduction of routine administration of probiotics.
doi:10.1371/journal.pone.0158136.g002
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nosocomial BSI rates in VLBW and ELBW infants (Table 5). Low birth weight, young gesta-
tional age and male gender were identified as risk factors for nosocomial BSI in VLBW and
ELBW infants (Table 5).
Discussion
This large observational multi-center study demonstrated that routine medication with dual-
strain probiotics in German neonatal wards was significantly associated with reduced inci-
dences of NEC and overall mortality. These beneficial effects of probiotics were already demon-
strated by several meta-analyses and systematic reviews including RCTs [8, 10, 11, 26–28, 36]
and observational studies [9], but have never been verified on such a large clinical scale.
Recently, Härtel et al. confirmed the association of probiotics with a reduced risk of NEC sur-
gery (OR 0.58, 95% CI, 0.37–0.91) in an observational study including 2,828 VLBW infants in
German NICUs [22]. Olsen and colleagues conducted a meta-analysis of 12 observational stud-
ies addressing the use of prophylactic probiotics for preterm infants [9]. 3 of these studies also
used Infloran with Lactobacillus acidophilus and Bifidobacterium infantis as probiotic agents
[19, 21, 22]. Two studies reported significant reduction of NEC by Infloran [19, 22]; one
reported the protective effect of Infloran in the subgroup of preterm infants fed with breast
milk [21]. Another recent retrospective cohort study demonstrated the protective effect of
Infloran on NEC in two German NICUs and one Swiss NICU [20]. Our study verified the
existing data and showed for the first time that probiotic treatment also improved survival of
preterm infants already suffering from NEC. This might be due to a milder course of disease
facilitated by probiotics and provides important information to improve the outcome of these
critically ill patients.
Critics of probiotic use are primarily worried about safety issues. Probiotics are living micro-
organisms and have the potential to cause infections, predominantly in preterm infants with a
premature immune system [37]. Our data supported the findings of recent meta-analyses and
systematic reviews that probiotics did not increase BSI rates [8–10, 12, 26–28]. In fact, we
showed that probiotic treatment was even protective against nosocomial BSI. One reason, why
this effect was not seen by other studies might be their smaller sample sizes. The beneficial
effects of probiotics were not only present in VLBW infants, but were even more pronounced
Table 2. Cox-proportional-hazard regression model with the outcome NEC in VLBW and ELBW infants.
VLBW ELBW
Parameter HR 95% CI;p-value HR 95% CI;p-value
Probiotics 0.484 0.378–0.619; p < 0.001 0.481 0.364–0.635; p < 0.001
Birth weight < 500 g 3.969 2.277–6.918; p < 0.001 2.184 1.355–3.521; p = 0.0013
Birth weight 500–749 g 3.723 2.463–5.628; p < 0.001 2.016 1.477–2.752; p < 0.001
Birth weight 750–999 g 1.903 1.301–2.783; p < 0.001
Gestational age (26 weeks
and younger)
1.812 1.312–2.502; p < 0.001 1.723 1.236–2.402; p = 0.0013
Large for gestational age
(LGA)
1.995 1.157–3.438; p = 0.013 2.315 1.235–4.340; p = 0.009
 60 VLBWs per year 0.625 0.478–0.817; p < 0.001 0.681 0.508–0.912; p = 0.01
Immediate postnatal
transport
1.938 1.129–3.328; p = 0.016 2.508 1.425–4.414; p = 0.014
Results of multivariable analysis: segmented regression analysis of interrupted time series using a Cox-proportional-hazard regression model with the
outcome NEC in 10,890 VLBW infants and 4,683 ELBW infants (<1000 g) in the time period 3 years before and 3 years since administration of routinely
use of probiotics. 95% CI–95% conﬁdence interval.
doi:10.1371/journal.pone.0158136.t002
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Fig 3. Overall mortality in VLBW infants (A) and in ELBW infants (B) before and after the routinemedication of probiotics. Half-yearly
overall mortality in 10,890 VLBW infants (A) and in 4,683 ELBW infants (B) treated in 44 neonatal departments before and after the routine
medication of probiotics. The grey line represents the trend of mortality (per 100 VLBW/ELBW infants) before and after the introduction of routine
administration of probiotics.
doi:10.1371/journal.pone.0158136.g003
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in the sub cohort of ELBW infants. Consequently, probiotics with licensing as a drug by a regu-
latory authority such as Infloran seem to be safe and beneficial even in this vulnerable
population.
This study is based on anonymized surveillance data. Thus, we have no additional informa-
tion on safety monitoring practice by neonatal units regarding probiotic bacteremia. However,
the surveillance data showed that 32 (3.8%, CI95% 2.65–5.28%) of 846 VLBW infants who
developed BSI and received probiotics died. Mortality rate was 6.2% (n = 49, CI 95% 4.7–8.1%)
Table 3. Cox-proportional-hazard regression model with the outcome overall mortality VLBW and ELBW-infants.
VLBW ELBW
Parameter HR 95% CI; p-value HR 95% CI; p-value
Time trend before
probiotics (per month)
1.018 1.006–1.030; p = 0.002 1.009 1.001–1.018; p = 0.036
Probiotics 0.604 0.442–0.826; p = 0.002 0.587 0.411–0.837; p = 0.003
Change in time trend after
probiotics (per month)
0.982 0.967–0.997; p = 0.021
Birth weight < 500 g 10.783 6.958–16.711; p < 0.001 8.353 6.058–11.517; p < 0.001
Birth weight 500–749 g 3.871 2.726–5.496; p < 0.001 2.768 2.206–3.473; p < 0.001
Birth weight 750–999 g 1.431 1.032–1.985; p = 0.032
Gestational age ( 26
weeks)
3.268 2.193–4.869; p < 0.001 1.980 1.493–2.624; p < 0.001
Gestational age (27 and 28
weeks)
1.597 1.129–2.259; p = 0.008
Male 1.569 1.340–1.838; p < 0.001 1.617 1.362–1.919; p < 0.001
Multiple birth 1.262 1.067–1.492; p = 0.007 1.348 1.126–1.615; p = 0.001
Vaginal 1.819 1.482–2.234; p < 0.001 2.081 1.681–2.577; p < 0.001
Emergency Caesarean
section
1.647 1.290–2.105; p < 0.001 1.713 1.315–2.232; p < 0.001
Small for gestational age
(SGA)
0.715 0.564–0.905; p = 0.005 0.603 0.465–0.781; p < 0.001
Large for gestational age
(LGA)
1.581 1.093–2.285; p = 0.015
< 30 VLBWs per year 0.746 0.609–0.915; p = 0.005 0.733 0.585–0.917; p = 0.007
 60 VLBWs per year 0.583 0.467–0.729; p < 0.001 0.572 0.448–0.732; p < 0.001
Immediate postnatal
transport
1.610 1.121–2.312; p = 0.010
Results of multivariable analysis: segmented regression analysis of interrupted time series using a Cox-proportional-hazard regression model with the
outcome overall mortality (without the time dependent variable NEC) in 10,890 VLBW-infants (665 deceased) and in 4,683 ELBW-infants (557 deceased).
95% CI–95% conﬁdence interval.
doi:10.1371/journal.pone.0158136.t003
Table 4. Cox-proportional hazard regression with the outcomemortality following NEC in VLBW and in ELBW-infants.
VLBW ELBW
Parameter HR 95%CI; p-value HR 95%CI; p-value
Probiotics 0.510 0.260–0.999; p = 0.0497 0.397 0.186–0.847; p = 0.017
Birth weight < 500 g 3.091 1.555–6.145; p = 0.001 3.105 1.538–6.270; p = 0.002
Vaginal delivery 2.129 1.048–4.326; p = 0.037 2.219 1.076–4.574; p = 0.031
Results of multivariable analysis: interrupted time series with segmented regression using Cox-proportional hazard regression with the outcome mortality
following NEC in 274 VLBW infants (44 deceased) and in 215 ELBW infants (39 deceased). 95% CI–95% conﬁdence interval.
doi:10.1371/journal.pone.0158136.t004
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Fig 4. Nosocomial BSI in VLBW (A) and in ELBW infants (B) before and after the routine medication of probiotics. Half-yearly incidences
of nosocomial BSI in 10,890 VLBW (A) and in 4,683 ELBW infants (B) treated in 44 neonatal departments before and after the routine medication
of probiotics. The grey line represents the trend of incidences of bloodstream infections (per 100 VLBW/ELBW infants) before and after the
introduction of routine administration of probiotics.
doi:10.1371/journal.pone.0158136.g004
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in the subgroup of VLBW infants who developed BSI and did not receive probiotics (n = 785).
Thus, probiotics reduced mortality in the sub cohort of VLBW infants with BSI (RR = 0.61,
CI95% = 0.39–0.93). However, for 16 VLBW infants (15 clinically diagnosed BSI, 1 laboratory-
confirmed BSI with “other bacteria” as causative agent) we could not exclude a probiotic strain
as causative agent of the BSI. No adverse events or cases of bacteremia with probiotic species
were reported in studies examining the effect of Infloran [19–22]. Even though probiotic bac-
teremia might be underestimated due to anaerobic culture conditions required by Bifidobacter-
ium spp. this seems to be an extremely rare event [24]. Three cases of bacteremia with
Bifidobacterium spp. in preterm infants who received Infloran are known in literature [24, 25].
All preterm infants recovered. Thus, in addition to the beneficial effects facilitated by probiotics
in preterm infants neonatologists should be aware of the potential of probiotic species to cause
infections.
The mechanisms by which probiotics work and might prevent preterm complications
remain unclear. Abnormal patterns of microbiota combined with a novel pathogen most likely
contribute to the etiology of NEC [38]. Investigations applying 16S rRNA sequencing revealed
that the composition of the gut microbiota in preterm infants suffering from NEC changed
between one week and< 72 hours before diagnosis of NEC [38]. The authors observed a
decrease of Firmicutes including the probiotic species Lactobacillus acidophilus by 32% [38].
These findings strongly suggest that a healthy gut microbiota established by probiotic treat-
ment prevents complications of preterm infants including NEC and BSI.
Main strengths of our study are the large sample size and the multi-center study design.
Data of more than 10,000 VLBW and more than 4,500 ELBW infants allowed us to identify
also small effects such as the protective effect of dual-strain probiotics on nosocomial BSI and
mortality following NEC. Further, our non-RCT design added data on effectiveness to the large
body of literature existing on the efficacy of dual-strain probiotics for preterm complications.
This study has limitations due to its observational, non-RCT study design. The anonymous
surveillance data used for this study did not provide information on protocols for probiotic
supplementation used by each NICU. Recommendations for dosage, frequency and duration
of probiotic prophylaxis with Infloran for preterm infants were recently published [20]. In
addition, we lack information on major changes in enteral feeding management or neonatal
Table 5. Cox-proportional-hazard regression model with the outcome nosocomial BSI in VLBW and in ELBW infants.
VLBW ELBW
Parameter HR 95% CI; p-value HR 95% CI; p-value
Probiotics 0.890 0.807–0.981; p = 0.019 0.832 0.741–0.936; p = 0.002
Birth weight < 500 g 2.746 2.192–3.441; p < 0.001 2.059 1.692–2.507; p < 0.001
Birth weight 500–749 g 1.976 1.668–2.341; p < 0.001 1.473 1.290–1.680; p < 0.001
Birth weight 750–999 g 1.344 1.156–1.563; p < 0.001
Gestational age ( 26
weeks)
2.349 1.886–2.925; p < 0.001 2.016 1.592–2.553; p < 0.001
Gestational age (27 and 28
weeks)
1.849 1.511–2.262; p < 0.001 1.598 1.247–2.047; p < 0.001
Gestational age (29 and 30
weeks)
1.334 1.087–1.636; p = 0.006
Male sex 1.242 1.126–1.371;p < 0.001 1.243 1.106–1.398; p < 0.001
Results of multivariable analysis: segmented regression analysis of interrupted time series using a Cox-proportional-hazard regression model with the
outcome nosocomial BSI in 10,890 VLBW infants and in 4,683 ELBW infants in the time period 3 years before and 3 years since introduction of routinely
use of probiotics. 95% CI–95% conﬁdence interval.
doi:10.1371/journal.pone.0158136.t005
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care that could influence the incidence of NEC. However, risk of confounding by these unac-
counted factors was reduced by interrupted time series analysis. This statistical method consid-
ered the trends before and after the implementation of probiotics as well as the change of the
outcome level after the intervention. Further, we adjusted the multivariable analysis for the fac-
tor year to consider the potential impact of general improvement of neonatal care on our
results. Year was not identified as independent risk or protective factor for NEC, mortality,
mortality following NEC and BSI. Thus, it is highly unlikely that the observed reductions of
preterm complications after the intervention are a result of general advances in neonatal care
only and cannot be attributed to the protective effect of the dual-strain probiotics. Another lim-
itation might be missed cases of NEC due to end of surveillance. Surveillance for a department
in NEO-KISS ended, if the VLBW infant weighed more than 1800 g, ii) died or was iii) trans-
ferred to another unit. In consequence, NEC would not be counted for infants weighing more
than 1800 g. However, the majority of NEC cases occur in preterm infants with birth weights
below 1500 g [4] with the most common age of onset of three days [39]. Further, NEC were not
documented by NEO-KISS, if a VLBW infant developed NEC after transfer from another unit
and this NEC was diagnosed during the first 72 h after admission to the new NICU. In most
cases, however, VLBW infants under development of NEC and / or below a weight of 1800 g
are not transferred to another unit. If a child was transferred for surgery because of NEC, this
case would be counted in the transferring department. The fact that Bell’s staging was not used
for diagnosis or classification of NEC in NEO-KISS is another important issue to discuss [29].
Even though, accuracy of Bell’s criteria has been discussed before [40, 41], it is commonly used
in neonatal probiotic literature to quantify severity of NEC [10, 27]. Our data did not account
for classification of NEC, even though histological diagnosis of NEC might constitute a surro-
gate parameter. A histologic specimen is an indicator of surgery and in consequence, severe
cases of NEC [33]. Based on these assumptions, we included the stratification of NEC type (No
NEC, surgical NEC, medical NEC, NEC type unknown) to the analysis. We re-analyzed our
multivariable model with the outcomes surgical NEC, medical NEC and NEC type unknown
adjusting for the same cofactors as the original model for all NEC cases. Dual-strain probiotics
were protective against all types of NEC suggesting that they also prevented severe cases. As we
mentioned before, histological diagnosis of NEC is not a mandatory input field in NEO-KISS.
Thus, assumptions underlying these analyses were speculative and should not be used for clini-
cal recommendations.
The study design applying interrupted time series analysis required patient data from 36
months before and 36 months after the implementation of probiotics in the NICUs. In conse-
quence, we could not include those German NICUs that implemented routine use of probiotics
after the first survey in 2011. In fact, the number of NICUs that implemented routine probiotic
use after 2011 is unknown. The most recent survey was conducted by Härtel and colleagues
among 46 German NICUs participating in the German Neonatal Network (GNN) in 2012.
Even in this very motivated subgroup, only 34 NICUs (74%) reported routine use of probiotics
[22]. In consequence, it is very likely that still many neonatal wards do not use routine probi-
otic medication for their preterm infants.
Conclusion
This large multi-center study adds data of more than 10,000 VLBW infants to the existing
body of evidence that prophylactic enteral administration of dual-strain probiotics significantly
reduces the incidences of NEC, overall mortality, mortality following NEC and BSI. If these
severe complications of preterm birth are to be reduced noticeably, the use of dual-strain probi-
otics should be considered in standard neonatal care, especially for ELBW infants.
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